Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.
<iframe src="https://statesidedaily.com/embed/cluster/d79d80e8ff23e3c459067f6ec9beb728b9aeda62" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease"></iframe>
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.
